Related references
Note: Only part of the references are listed.Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies
Gihanna Galindez et al.
NATURE COMPUTATIONAL SCIENCE (2021)
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model
Milena Aksentijevich et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2020)
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
Alexandre Sepriano et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Christopher T Ritchlin et al.
LANCET (2020)
Reflections on 'older' drugs: learning new lessons in rheumatology
S. A. Kerrigan et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Lethal Infectious Diseases as Inborn Errors of Immunity: Toward a Synthesis of the Germ and Genetic Theories
Jean-Laurent Casanova et al.
Annual Review of Pathology-Mechanisms of Disease (2020)
Mycobacterial Infections Potentiated by Biologics
Cassandra Calabrese et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2020)
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis
Stefano Alivernini et al.
NATURE MEDICINE (2020)
RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis Flares
Dana E. Orange et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tolerance in the Age of Immunotherapy
Jeffrey A. Bluestone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?
Christopher Ma et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2019)
Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
Rita Kansal et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study
Ashley Budu-Aggrey et al.
PLOS MEDICINE (2019)
Distinct fibroblast subsets drive inflammation and damage in arthritis
Adam P. Croft et al.
NATURE (2019)
Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol
Mariam Al-Laith et al.
TRIALS (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC)
Gloria Lliso-Ribera et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Tolerising cellular therapies: what is their promise for autoimmune disease?
Chijioke H. Mosanya et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?
Stefan Siebert et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
Danielle M. Gerlag et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs
Amit D. Parulekar et al.
CURRENT OPINION IN PULMONARY MEDICINE (2018)
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
K. M. Sullivan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis
Andrew Schrepf et al.
NATURE COMMUNICATIONS (2018)
2016 update of the EULAR recommendations for the management of early arthritis
Bernard Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Psoriasis pathogenesis and the development of novel targeted immune therapies
Jason E. Hawkes et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Pathogenetic insights from the treatment of rheumatoid arthritis
Iain B. McInnes et al.
LANCET (2017)
Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis
Deepak A. Rao et al.
NATURE (2017)
TIMELINE Managing rheumatic and musculoskeletal diseases - past, present and future
Gerd R. Burmester et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
Trial of Tocilizumab in Giant-Cell Arteritis
J. H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dosing down with biologic therapies: a systematic review and clinicians' perspective
Christopher J. Edwards et al.
RHEUMATOLOGY (2017)
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis
Frieda A. Koopman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
Iain B. McInnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Toward a cytokine-based disease taxonomy
Georg Schett et al.
NATURE MEDICINE (2013)
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
Naomi Schlesinger et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway
Melissa M. Matzelle et al.
ARTHRITIS AND RHEUMATISM (2012)
Mucosal healing in inflammatory bowel diseases: a systematic review
Markus F. Neurath et al.
GUT (2012)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis
William P. Arend et al.
NATURE REVIEWS RHEUMATOLOGY (2012)
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
C Grigor et al.
LANCET (2004)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
Share Paper
